Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons drs. M. Nijland

Publicaties

A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients

A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics

European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours

FDG-PET/CT discriminates between patients with and without lymphomas in primary Sjögren's syndrome

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA

R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial

R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study

Zoonotic Transmission of Vaccine-Derived Bordetella bronchiseptica

Lees meer

Pers/media

Rituximab Biosimilars Versus Originator: Comparing Long-Term Survival Benefit in DLBCL

Medtalks:Diffuus Grootcellig B-cellymfoom 2018